LSM-775
lysergic acid morpholide
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
LSM-775 (lysergic acid morpholide) is a synthetic psychedelic of the lysergamide class. It is a close structural relative of LSD, but far less potent. It activates serotonin receptors in two opposing ways — generating and simultaneously suppressing psychedelic signals — producing a body-heavy, muted result.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, DMT, other lysergamides show less
Albert Hofmann synthesized LSM-775 at Sandoz Laboratories in the mid-1950s, searching for new lysergic acid derivatives.[3] Three small human studies confirmed it was 5 to 10 times weaker than LSD with a heavier side-effect profile; Sandoz abandoned development, and the compound lay dormant until it resurfaced on the research chemical market in 2013.[1] It remains unscheduled in most countries and circulates in small quantities among research chemical users.
Subjective effects include nausea, sedation, mild geometric visual patterns, mood shifts, and pervasive bodily heaviness. The experience is defined by somatic weight — a nauseogenic, heavy baseline through which faint perceptual changes emerge, less a psychedelic journey than a body burden with psychedelic undertones.[4] Vomiting, rapid heart rate, heavy sweating, and cardiovascular discomfort are characteristic unwanted effects.
LSM-775 produces no physical dependence, and no lethal dose has been established — rapid tolerance makes compulsive redosing self-limiting.[5] The dominant hazard is the pronounced body load: severe nausea, vomiting, and cardiovascular stress at effective doses, plus a theoretical risk of heart valve damage with repeated use.[1] Understanding rests on a single 2018 pharmacological study and sparse user reports — no clinical trials or toxicity data exist.
History[edit]
Discovery
Albert Hofmann synthesized LSM-775 at Sandoz Laboratories in Basel in the mid-1950s, as part of a systematic exploration of lysergic acid derivatives.[1][6] The first human data appeared in 1957: 75 µg produced roughly the same effect as 50 µg of LSD, but with shorter duration.[3] Two further small studies confirmed it was 5 to 10 times less potent than LSD and unable to produce more than threshold psychedelic effects.[1]
Institutional trajectory
Sandoz did not pursue LSM-775 further. Unlike LSD, which the company marketed as Delysid for psychiatric research, LSM-775's weak potency and unfavorable profile — sedation and nausea at effective doses — made it unsuitable for clinical development.
Modern era
LSM-775 reappeared in 2013 on the research chemical market, presumably based on historical reports of weak LSD-like effects.[1] This prompted the first modern pharmacological characterization by Brandt and colleagues in 2018 — the only published study specific to the compound.[1] It remains unscheduled in most jurisdictions and circulates in small quantities.
The designation "LSM" comes from the German Lysergsäure-Morpholid (lysergic acid morpholide), and "775" is its Sandoz compound number — the same naming convention as LSD-25. It is known mainly among research chemical enthusiasts as an example of how a small structural change to LSD can dramatically alter the character of the experience.
Chemistry[edit]
Structural class
LSM-775 belongs to the lysergamide family, sharing the same four-ring ergoline core as LSD, 1P-LSD, and AL-LAD. The defining difference from LSD is a morpholine ring in place of LSD's two flexible ethyl groups — a structural change that constrains the molecule's shape and alters how it fits into serotonin receptor binding sites.[7]
Molecular identity
| Molecular formula | C₂₀H₂₃N₃O₂ |
| Molecular weight | 337.4 g/mol |
The morpholine ring contains an oxygen atom absent in LSD, making LSM-775 slightly less lipophilic. The absolute configuration of its two stereocenters has been confirmed by X-ray crystallography of the hemitartrate salt.[1]
Pharmacology[edit]
Mechanism of action
LSM-775 acts at two serotonin receptor types simultaneously, with opposing effects.[1] One generates psychedelic activity; the other — more potently activated — produces sedation and actively suppresses that psychedelic signal. Psychedelic-type behavior only appears in animal models when the suppressive pathway is blocked first[1][2] — a pattern also seen with 5-MeO-DMT and the non-hallucinogenic drug lisuride.[2][8][9]
Pharmacokinetics
No pharmacokinetic studies have been published for LSM-775. Absorption, distribution, and elimination are entirely uncharacterized. By analogy with LSD, liver enzymes likely handle metabolism, and slow metabolizers probably experience stronger and longer effects.[10]
Historical reports describe the duration as shorter than LSD at comparable doses.[3][4] Community data suggest onset at 10–30 minutes and total duration of 6–10 hours.[11] inferred
Neuroscience[edit]
No direct neuroimaging, electrophysiological, or neuroplasticity data have been published for LSM-775. The following draws on class-level evidence from serotonergic psychedelics and LSM-775's specific pharmacological profile. inferred
Where it acts
Classical serotonergic psychedelics produce their effects by activating receptors on neurons in the prefrontal cortex, disrupting the brain's normal filtering of sensory input.[12] LSM-775 engages this pathway partially, while simultaneously fully activating a second receptor type that slows neuronal firing and dampens arousal — introducing a powerful brake on the psychedelic signal.
The behavioral result is stark: no psychedelic response in animals unless the suppressive pathway is blocked first.[1] The likely experience is a partially loosened perceptual state — far less disruption than LSD or psilocybin. The sedation and nausea users report[4] likely reflect the suppressive pathway acting on arousal and nausea circuits in the brainstem.
Why it matters
Psychedelics are thought to work partly by loosening rigid thinking patterns — increasing the brain's flexibility through serotonin receptor activation. LSM-775's suppression of that activation would constrain this effect, predicting mild perceptual loosening without the deeper dissolution seen with LSD or psilocybin. Whether it promotes new brain connections, as other serotonergic psychedelics do, is unknown.
- Does LSM-775 promote new brain connections at pharmacologically relevant doses, and are these proportional to its partial receptor activation?
- What happens to the morpholine ring when metabolized — does it produce active breakdown products?
- Does LSM-775 affect dopamine systems, as its shared structure with LSD would predict?
Subjective Effects[edit]
The LSM-775 experience is built on a heavy, nauseogenic foundation. Physical weight, bodily discomfort, and cardiovascular awareness persist throughout, with faint psychedelic shifts — mild visuals, mood changes — emerging through that baseline rather than dominating it. The body is the foreground; altered perception is the background.
Relative to LSD, LSM-775 is notably less visual and more sedating, characterized by somatic burden rather than cognitive or perceptual expansion. Within the lysergamide family, it most closely resembles a low-dose experience of ergine (LSA) — muted and body-heavy — though the underlying mechanisms differ.
Effect Grid
A recognizable but attenuated psychedelic state emerges. Color alteration takes on the earthy, sepia-toned quality characteristic of LSM-775. Mild geometry, visual drifting, and internal hallucinations are present but muted relative to LSD at equivalent subjective intensity. Depth perception distortion and perspective distortion may be noticed.
Body load is significant and defines the experience at this tier: nausea is persistent, sedation and dreaminess are prominent, and spontaneous body sensations — sweating, temperature dysregulation, cardiovascular awareness — are common. Pupil dilation is expected. Appetite is strongly suppressed.
Thought connectivity and conceptual thinking are enhanced. Introspection deepens. Time alteration is noticeable. The experience lasts 6–9 hours with residual fatigue afterward.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Holotropic state · Sleep-transition hallucinations · Tracers · Light sensitivity · Visual breathing · Color alteration · Visual morphing · Auditory enhancement · After-images · Visual haze / noise · Sound sensitivity · Brightness alteration · Depth perception distortion · Symmetrical texture repetition · Environmental patterning · Perspective distortion · Touch enhancement · Dreaming enhancement · Spatial disorientation · Proprioceptive distortion · Ganzfeld effect · Auditory distortion · Visual diffraction · Peripheral vision distortion · Synesthesia · Visual melting · Auditory misinterpretation · Vestibular distortion · Peripheral misidentification · Visual acuity enhancement · Taste enhancement · Olfactory enhancement · Visual magnification · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Object activation · External hallucinations · Visual recursion · Auditory hallucinations · Perspective hallucinations · Visual flipping · Visual scenery slicing · Environmental orbism / cubism · Visual processing suppression · Shadow people · Persisting hallucinations
Visual breathing · Color alteration · Visual morphing · Auditory enhancement · After-images · Visual haze / noise · Sound sensitivity · Brightness alteration · Depth perception distortion · Symmetrical texture repetition · Environmental patterning · Perspective distortion · Touch enhancement · Dreaming enhancement · Spatial disorientation · Proprioceptive distortion · Ganzfeld effect · Auditory distortion · Visual diffraction · Peripheral vision distortion · Synesthesia · Visual melting · Auditory misinterpretation · Vestibular distortion · Peripheral misidentification · Visual acuity enhancement · Taste enhancement · Olfactory enhancement · Visual magnification · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Object activation · External hallucinations · Visual recursion · Auditory hallucinations · Perspective hallucinations · Visual flipping · Visual scenery slicing · Environmental orbism / cubism · Visual processing suppression · Shadow people · Persisting hallucinations
Stimulation · Spontaneous body sensations · Appetite suppression · Wakefulness · Nausea · Muscle tension · Heart rate perception changes · Tingling / electric sensations · Insomnia · Physical fatigue · Tactile euphoria · Excessive sweating · Dizziness · Restlessness · Vibrations / buzzing · Dry mouth · Laughter fits · Bodily pressures · Bodily lightness · Sexual arousal enhancement · Yawning · Body schema distortion · Trembling · Headache · Bruxism · Involuntary body movements · Bodily heaviness · Dehydration sensation · Nystagmus (eye wobbles) · Motor control impairment · Breathing alteration · Watery eyes · Vomiting · Bodily dissociation · Tactile hallucination
Wakefulness · Nausea · Muscle tension · Heart rate perception changes · Tingling / electric sensations · Insomnia · Physical fatigue · Tactile euphoria · Excessive sweating · Dizziness · Restlessness · Vibrations / buzzing · Dry mouth · Laughter fits · Bodily pressures · Bodily lightness · Sexual arousal enhancement · Yawning · Body schema distortion · Trembling · Headache · Bruxism · Involuntary body movements · Bodily heaviness · Dehydration sensation · Nystagmus (eye wobbles) · Breathing alteration · Watery eyes · Vomiting · Bodily dissociation · Tactile hallucination
Thought connectivity · Aesthetic enhancement · Openness enhancement · Multiple thought streams · Cognitive flexibility · Pattern recognition enhancement · Novelty enhancement · Thought acceleration · Increased nature relatedness · Immersion enhancement · Creativity enhancement · Thought loops · Confusion · Analysis enhancement · Humor enhancement · Focus suppression · Cognitive impairment · Synchronicity · Cognitive fatigue · Information processing enhancement · Motivation enhancement · Language enhancement · Memory fragmentation · Thought disorganization · Memory replays · Language suppression · Information processing suppression · Focus enhancement · Cognitive dysphoria · Delusions of sobriety · Memory suppression · Motivation suppression · Thought organization · Amnesia
Multiple thought streams · Cognitive flexibility · Pattern recognition enhancement · Novelty enhancement · Thought acceleration · Increased nature relatedness · Immersion enhancement · Creativity enhancement · Thought loops · Confusion · Analysis enhancement · Humor enhancement · Focus suppression · Cognitive impairment · Synchronicity · Cognitive fatigue · Information processing enhancement · Motivation enhancement · Language enhancement · Memory fragmentation · Thought disorganization · Memory replays · Language suppression · Information processing suppression · Focus enhancement · Cognitive dysphoria · Memory suppression · Motivation suppression · Thought organization · Amnesia
Empathy enhancement · Simultaneous emotions · Catharsis · Anxiety · Anxiety suppression · Dysphoria · Irritability
Anxiety suppression · Dysphoria · Irritability
Sociability enhancement · Disinhibition · Trust enhancement · Communication enhancement · Flow state · Compulsive behavior reduction · Automaticity · Social disconnection · Communication suppression · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration · Telepathic feelings · Cognitive disconnection
Flow state · Compulsive behavior reduction · Automaticity · Social disconnection · Communication suppression · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration · Telepathic feelings · Cognitive disconnection
Time cessation
Entity contact · Transpersonal visions · Transpersonal memory access · Death-rebirth sequence · Voidness · Cessation · Near-death experience
Voidness · Cessation · Near-death experience
Lucidity enhancement · Recursive awareness
Timeline
First alerts emerge as mild somatic awareness — light nausea, subtle bodily heaviness, and faint mood shift. No perceptual changes yet.
Body load builds noticeably: nausea intensifies, sedation and heaviness set in. First perceptual shifts appear — subtle color alteration and brightness changes.
Maximum perceptual and somatic effects. Sepia-toned color alteration, mild geometry, and internal hallucinations present. Nausea peaks with possible vomiting.
Perceptual effects gradually recede while body load persists. Nausea fades before visual effects. Sedation and physical fatigue remain prominent.
Residual physical fatigue and possible mild mood effects. Appetite may slowly return. Cognitive baseline approaches normal but subtle sedation may linger.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for LSM-775 in any species, and no controlled toxicity studies have been conducted.[1] By class analogy, serotonergic psychedelics have extremely wide safety margins in animal models, and no death has been attributed solely to LSD despite decades of widespread use.[12] This is expected to apply to LSM-775, but remains unconfirmed. safety citation needed
No case reports of overdose, hospitalization, or fatality involving LSM-775 have been published.
Body load
At effective doses, LSM-775 produces severe nausea, vomiting, rapid heart rate, heavy sweating, and elevated blood pressure.[4] This somatic burden is more intense than typically seen with LSD or psilocybin at equivalent psychedelic doses and is the compound's most significant acute concern.
Cardiac considerations
LSM-775 activates a receptor type — present in heart valve tissue — whose chronic stimulation is the established mechanism behind drug-induced valve disease, documented with related ergot-derived drugs.[1] No cardiac safety data specific to LSM-775 exist. The concern applies only to repeated or chronic exposure. safety citation needed
Psychological Risks
The standard psychological risks of serotonergic psychedelics apply: acute anxiety, confusion, thought loops, and challenging experiences — particularly in stressful settings or in people with pre-existing psychiatric vulnerabilities. Lasting perceptual disturbances — HPPD — are a recognized class-level concern.[13]
LSM-775's weaker hallucinogenic potency may reduce the intensity of perceptual challenges but does not eliminate psychological distress risk. The sedating, nauseogenic quality can itself produce dysphoria. Personal or family history of psychotic disorders, schizophrenia, or bipolar disorder is a risk factor for acute psychiatric crisis with any serotonergic psychedelic.
Tolerance and Dependence
Serotonergic psychedelics produce rapid tolerance through receptor adaptation, within 24 hours of a single dose.[5] Cross-tolerance between psychedelics operates through the same mechanism.[5] Community data for LSM-775 report tolerance building almost immediately, with a half-life of approximately 6 days and full reset at 14 days.[11]
No abuse liability has been documented for LSM-775. Serotonergic psychedelics are generally non-addictive as a class,[12] and rapid tolerance development mechanically discourages compulsive redosing.
Drug Interactions
Serotonin syndrome risk
Combining LSM-775 with serotonergic medications risks triggering serotonin syndrome — a dangerous state of serotonin overload causing muscle rigidity, high fever, rapid heart rate, and agitation. Tramadol presents a dangerous interaction by this mechanism.[14] SSRIs and SNRIs carry a theoretical risk; a review of antidepressant-psychedelic combinations found no confirmed cases in clinical studies, though most studies excluded participants on serotonergic medications.[15] SSRIs may also reduce LSM-775's psychedelic effects.
MAOI combinations present the most severe theoretical risk: blocking serotonin breakdown could amplify LSM-775's serotonergic activity beyond safe levels.
Seizure threshold interactions
Lithium combined with lysergamides is a recognized seizure risk. No LSM-775-specific data exist, but the combination is contraindicated by class analogy. citation needed
Cannabis
The interaction between LSM-775 and cannabis is uncharacterized. Cannabis has been reported to intensify and prolong serotonergic psychedelic effects in user reports, but no controlled data exist. citation needed
Contraindications
Absolute contraindications:
- Psychotic disorders or personal history of psychosis — serotonergic psychedelics may trigger or worsen psychotic episodes.
- Concurrent MAOI use — risk of severe serotonin syndrome.
- Concurrent tramadol use — serotonin syndrome risk.[14]
Relative contraindications:
- Bipolar disorder — risk of triggering manic episodes, particularly in bipolar I.
- Family history of psychotic disorders — elevated risk of psychedelic-triggered psychosis.
- Concurrent SSRI/SNRI use — theoretical serotonin syndrome risk, though confirmed cases are absent from the literature.[15] Likely reduced psychedelic effects.
- Heart conditions — the documented cardiovascular effects (rapid heart rate, elevated blood pressure) suggest caution.[4]
- Concurrent lithium use — seizure risk by class analogy with other lysergamides. citation needed
Harm Reduction[edit]
Forms & Identification
LSM-775 has no pharmaceutical formulations and circulates exclusively through the research chemical market as powder, crystalline salt, or blotter. Analytical confirmation is critical: no field test can distinguish LSM-775 from LSD or other ergoline derivatives. Reagent tests (Ehrlich, Hofmann) confirm the presence of an indole or ergoline compound but cannot identify the specific substance. Laboratory analysis through an energy-control or similar service is the only reliable method.
Dosing precision is essential. LSM-775 is active in the high-microgram to low-milligram range, and research chemical batches vary in purity. A milligram-precision scale (0.001 g) is required for preparing volumetric solutions. Measuring individual doses from loose powder without a scale is unsafe.
Guidelines
- Test all material with Ehrlich and Hofmann reagents to confirm the presence of an ergoline compound. Send a sample for laboratory analysis if possible.
- Use a milligram-precision scale. Prepare volumetric solutions for accurate dosing at the microgram level.
- Start with a low dose (250–500 µg oral) to assess individual response before increasing. The body load scales with dose.
- Have anti-nausea measures available: ginger, light meals beforehand, or an empty stomach — preferences vary, but preparation helps.
- Arrange a comfortable environment with easy bathroom access. Keep water available.
- Have a sober, trusted companion present, especially for higher doses or first experiences.
- Allow at least 14 days between uses for full tolerance reset.
- Do not redose during the experience. The slow onset (10–30 minutes) and extended body load make stacking doses unpredictable.
Set & Setting
LSM-775's pronounced somatic burden makes environment preparation more important than with cleaner-feeling psychedelics. Nausea and vomiting are common at effective doses — a bathroom and a comfortable place to lie down should be available before dosing. A calm, familiar environment with a trusted companion is strongly recommended, especially for a first experience.
The attenuated psychedelic intensity does not eliminate psychological risk. Physical discomfort combined with residual perceptual shifts can produce dysphoria in a stressful or unfamiliar setting.
Aftercare & integration. The somatic intensity of the LSM-775 experience can leave the body depleted. Prioritize hydration and light nutrition in the hours following, particularly if vomiting occurred. Rest is advisable — sedative effects may persist as fatigue into the following day.
Psychological integration follows the same principles as other psychedelic experiences. Journaling, conversation with a trusted person, or quiet reflection can help process insights or difficult material. If distressing thoughts or perceptual changes persist beyond 48 hours, consult a mental health professional experienced with psychedelic experiences.
Recovery & Support
Serotonergic psychedelics are generally non-addictive, and LSM-775's pronounced body load and rapid tolerance further discourage compulsive use. Problematic patterns — using to escape rather than explore, escalating frequency despite negative effects — warrant honest self-assessment.
If use is causing distress or interfering with daily functioning, the Fireside Project (call or text 62-FIRESIDE) offers confidential, non-judgmental peer support. For persistent psychological difficulty, a therapist experienced with psychedelic integration can help.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe chest pain or heart palpitations that do not subside
- Uncontrollable vomiting or inability to keep fluids down for more than 2 hours
- Seizure or loss of consciousness
- Complete dissociation from reality with risk of self-harm
- Signs of serotonin syndrome: muscle rigidity, high fever, tachycardia, agitation (if combined with serotonergic drugs)
Immediate steps:
- Move the person to a safe, quiet space.
- If vomiting, place in the recovery position to prevent aspiration.
- Call emergency services if symptoms are severe or worsening — do not wait.
- Stay with the person. Speak calmly and provide reassurance.
- Do not induce vomiting. Do not restrain unless there is immediate danger.
What to tell the dispatcher:
State the substance name (LSM-775 or lysergic acid morpholide), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
LSM-775 is not listed in the United Nations Convention on Psychotropic Substances, and most jurisdictions have not enacted substance-specific controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled | Not listed in DEA schedules. Federal Analogue Act applicability is legally uncertain — the morpholine ring may place LSM-775 outside the structural scope of specifically covered ergoline analogs.[16] |
| United Kingdom | Psychoactive Substances Act 2016 | Not listed in the Misuse of Drugs Act 1971. Production, supply, import, and export are illegal under the PSA. Possession for personal use is not criminalized. |
| Germany | NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Controlled since July 18, 2019. Production and import with intent to distribute, administration to another person, and trading are punishable. Possession for personal use is illegal but not penalized. |
| Switzerland | Betäubungsmittelverzeichnis, Verzeichnis E | Controlled as a defined derivative of lysergic acid under point 263. Scientific and industrial use is exempt. |
| Canada | Not controlled | Not a controlled substance as of May 2026.[16] |
| Australia | Not explicitly scheduled | No evidence of specific TGA scheduling. May fall under state or territory analogue frameworks, but no explicit schedule decision has been identified. |
Analogue act considerations
In the United States, the Federal Analogue Act could theoretically extend Schedule I controls to LSM-775 given its structural relationship to LSD — but the morpholine ring is a significant structural departure, placing the compound in a legal grey area.[16] No case law specific to LSM-775 prosecution under the Act has been identified.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current law before acting.
references
- [1] ^abcdefghijklmBrandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL (2018) Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) — Drug Testing and Analysis doi:10.1002/dta.2222
- [2] ^abcHalberstadt AL, Koedood L, Powell SB, Geyer MA (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice — Journal of Psychopharmacology doi:10.1177/0269881110388326
- [3] ^abcGogerty JH, Dille JM (1957) Pharmacology of d-lysergic acid morpholide (LSM) — The Journal of Pharmacology and Experimental Therapeutics PMID:13476356
- [4]
- [5] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6] ^Tasker NR, Wipf P (2021) Biosynthesis, total synthesis, and biological profiles of Ergot alkaloids — The Alkaloids: Chemistry and Biology doi:10.1016/bs.alkal.2020.08.001